Transpeptidase mutant as well as preparation method and application thereof

By modifying the amino acid sequence of Sortase A enzyme, the mutants SrtA XS228 and SrtA XS236 with a wider recognition range were designed, which solved the problem of the limitations of Sortase A enzyme recognition sequence, achieved more efficient peptide chain ligation effect, and expanded their application range.

CN119082072APending Publication Date: 2024-12-06XIUSHI BIOMEDICAL (NANTONG) CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411531643.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2023-12-26
Filing Date
2024-10-30
Publication Date
2024-12-06

AI Technical Summary

Technical Problem

The existing Sortase A enzyme can only recognize the LPXTG sequence at the C-terminal, limiting its application range in practical applications.

Method used

By artificially modifying the amino acid sequence of SortaseA, the mutants SrtA XS228 and SrtA XS236 were designed, and their recognition sequences were modified to (L/F/A/D/S/G)+(P/A)+XTG were expanded to identify them. sequence range.

Benefits of technology

The mutants are able to recognize a wider range of C-terminal sequences, significantly improve the efficiency and product concentration of peptide chain ligation, and are suitable for the cyclization and ligation of polypeptides or proteins, expanding the scope of application.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119082072A_ABST
    Figure CN119082072A_ABST
Patent Text Reader

Abstract

The invention discloses a transpeptidase mutant as well as a preparation method and application thereof, the transpeptidase mutant comprises SrtA XS228 or SrtA XS236, the amino acid sequence of the SrtA XS228 is as shown in SEQ ID NO.2, and the amino acid sequence of the SrtA XS236 is as shown in SEQ ID NO.3. The invention further discloses a preparation method and application of the transpeptidase mutant. The transpeptidase mutant (SrtA XS228 or SrtA XS236) with an amino acid sequence as shown in SEQ ID NO.2 or SEQ ID NO.3 is disclosed for the first time, and a nucleotide sequence for coding the transpeptidase mutant is disclosed; the transpeptidase mutant can recognize polypeptide or protein with the C terminal containing (L / F / A / D / S / G) + (P / A) + XTG sequence, and the application range is wider; under the same condition, the concentration of a polypeptide product successfully connected with the transpeptidase mutant is higher, the connection efficiency of the transpeptidase mutant is obviously higher than that of conventional transpeptidase, and the transpeptidation effect is better.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biotechnology, in particular to a transpeptidase mutant and a preparation method and application thereof. Background Art

[0002] Among the chemical selective connection methods that have been discovered, the method based on ester-thioester bond conversion is the most widely used, and the most classic of these is native chemical ligation (NCL). This organic reaction applicable to biomacromolecules only requires a carbon-terminal peptide with a thioester group and another nitrogen-terminal peptide with a cysteine ​​residue to complete the coupling of two peptide chains under mild reaction conditions. However, the NCL reaction has many limitations in practical applications, especially in the introduction of thioester bonds in solid-phase synthesis, which is still difficult.

[0003] One strategy to replace the NCL reaction is to use the bioenzymatic method. In recent years, it has been found that the transpeptidase SortaseA isolated from Staphylococcus aureus has good reactivity and connection specificity in protein / peptide synthesis and modification reactions. SortaseA can specifically bind to the LPXTG sequence near the C-terminus of the protein / peptide, cut the peptide bond between threonine and glycine, and connect it to another peptide chain containing a glycine residue at the N-terminus through a peptide bond. Due to the high specificity of this reaction, the Sortase enzyme method has been widely used in protein / peptide synthesis and modification. However, SortaseA must require that there must be a specific sequence such as LPXTG near the C-terminus of the connected polypeptide or protein, which has led to great limitations in the practical application of the peptide chain connection method based on the Sortase enzyme method. Summary of the invention

[0004] In view of the shortcomings of the prior art described above, the purpose of the present invention is to provide a transpeptidase mutant to solve the problem that SortaseA in the prior art can only recognize the LPXTG sequence at the C-terminus, which limits its application. At the same time, the present invention will also provide a method for preparing the transpeptidase mutant; in addition, the present invention will also provide the application of the transpeptidase mutant.

[0005] In order to achieve the above-mentioned object and other related objects, the present invention provides the following technical solutions: In the first aspect of the present invention, the present invention artificially transforms the conventional transpeptidase Sortase A, replaces the amino acid sequence of the conventional transpeptidase Sortase A as shown in SEQ ID NO.1 with the amino acid sequence as shown in SEQ ID NO.2, and names the transpeptidase mutant SrtA XS228; or replaces the amino acid sequence of the conventional transpeptidase Sortase A as shown in SEQ ID NO.1 with the amino acid sequence as shown in SEQ ID NO.3, and names the transpeptidase mutant SrtA XS236.

[0006] Furthermore, the DNA molecule encoding the SrtA XS228 has a nucleotide sequence as shown in SEQ ID NO.5; the DNA molecule encoding the SrtA XS236 has a nucleotide sequence as shown in SEQ ID NO.6.

[0007] The DNA molecule encoding the conventional transpeptidase Sortase A has a nucleotide sequence as shown in SEQ ID NO. 4. The present invention predicts the modular structure of the conventional transpeptidase Sortase A, artificially designs and optimizes the sequence, thereby obtaining SrtA XS228 and SrtA XS236, and changes the C-terminal specific sequence LPXTG originally required for peptide chain connection to (L / F / A / D / S / G)+(P / A)+XTG.

[0008] The amino acid sequence involved in the present invention is as follows: (1) Amino acid sequence of SrtA: MKKWTNRLMTIAGVVLILVAAYLFAKPHIDNYLHDKDKDEKIEQYDKNVKEQASKDKKQQAKPQIPKDKSKVAGYIEIPDADIKEPVYPGPATPEQLNRGVSFAE ENESLDDQNISIAGHTFIDRPNYQFTNLKAAKKGSMVYFKVGNETRKYKMTSIRDVKPTDVGVLDEQKGKDKQLTLITCDDYNEKTGVWEKRKIFVATEVK (SEQ ID NO.1); (2) Amino acid sequence of SrtA XS228: MKKWTNRLMTIAGVVLILVAAYLFAKPHIDNYLHDKDKDEKIEQYDKNVKEQASKDKKQQAKPQIPKDKSKVAGYIEIPDADIKEPYPGPATPEQLNRGVSFAE ENESLDDQNISIAGHTFIDRPNYQFTNLKAAKKGSMVYFKVGNETRKYKMTSIRDVKPTDVGVLDEQKGKDKQLTLITCDDYNEKTGVWEKRKIFVATEVK (SEQ ID NO.2); (3) Amino acid sequence of SrtA XS236: MAKWTNLMTIPGVVLILVAALLFAKPHIDNYLHDKDKDEKTEQYDKNVKEQASKDKKQRAKPQIPKDKSKVAGYIEDPDADIKEPPYPGPATPEQLNRGVSFAE ENESLDDQNISTAGFTFIDRPNYQFTNLKAAKKASMVYFKVGNETRKYKMTSIRPVKPTDVGVLDEQKGKDKQLTLITCCDYNEKTGVWEKRKIFVATEVK (SEQ ID NO.3).

[0009] The nucleotide sequences involved in the present invention are as follows: (1) Nucleotide sequence encoding SrtA: ATGAAAAAGTGGACTAACCGGCTGATGACTATTGCGGGTGTGGTACTGATTCTTGTAGCGGCGTATCTGTTTGCCAAACCGCACATCGATAACTATTTACATGACAAAGACAAGGATGAAAAGATCGAACAATATGATAAGAACGTGAAGGAGCAGGCGAGTAAAGACAAAAAACAACAAGCGAAGCCGCAAATCCCAAAGGATAAATCCAAAGTGGCCGGTTACATTGAAATTCCTGATGCGGACATCAAGGAACCGGTTTATCCGGGGCCTGCGACCCCCGAGCAGCTGAATCGTGGCGTGTCGTTTGCTGAGGAAAATGAAAGCCTGGATGACCAAAATATCTCAATCGCTGGGCACACTTTCATAGATAGGCCTAACTATCAGTTTACGAACCTGAAAGCCGCAAAAAAAGGCTCTATGGTTTATTTTAAGGTAGGTAACGAAACCAGGAAGTACAAAATGACCAGTATCCGAGACGTGAAGCCTACAGACGTTGGTGTTCTGGATGAACAGAAAGGCAAAGACAAACAGCTGACCCTCATTACGTGCGATGATTACAATGAAAAGACCGGCGTATGGGAAAAACGTAAAATCTTTGTCGCTACGGAAGTAAAGTAA (SEQ ID NO.4); (2) Nucleotide sequence encoding SrtA XS228: ATGAAAAAATGGACCAATCGTCTCATGACGATAGCTGGCGTGGTGCTCATCCTAGTTGCTGCCTACTTATTCGCAAAACCGCATATAGATAACTATCTGCATGATAAGGACAAGGACGAGAAAATCGAGCAGTATGATAAAAATGTGAAAGAGCAGGCGAGCAAAGACAAAAAGCCTCAGGCTAAGCCCCCAATCCCGAAAGATAAATCCAAAGTAGCGGGTTACATTGAGATTCCAGATGCCGACATTAAAGAACCATACCCGGGTCCTGCTACTCCGGAACAGCTCAACCGTGGTGTGTCATTCGCAGAAGAAAATGAGTCTTTAGATGATCAGAACATCTCTATAGCAGGCCACACCTTCATTGATCGACCTAATTATCAGTTTACGAACCTGAAAGCGGCAAAAAAAGGTAGCATGGTGTATTTCAAAGTGGGCAACGAAACCCGCAAGTATAAGATGACCAGCATCAGAGATGTGAAACCTACCGACGTCGGCGTGCTTGACGAACAGAAAGGTAAAGACAAACAGCTTACACTGATCACCTGCGATGATTACAACGAAAAAACCGGCGTGTGGGAGAAACGCAAAATCTTCGTCGCCACCGAGGTGAAATAA(SEQ ID NO.5); (3) Nucleotide sequence encoding SrtA XS236: (SEQ ID NO.6).

[0010] Furthermore, the method for constructing the amino acid sequence of the transpeptidase mutant comprises the following specific steps: a. Predict the modular structure of SrtA; b. According to the prediction results, the SrtA sequence is modified to form a mutation library; c. Predict the possible effects of mutations on protein structure and function, and preliminarily select high-scoring sequences; d. Conduct enzyme activity experiments on the selected sequences and select the sequences with better effects.

[0011] Thus, the transpeptidase mutant SrtA XS228 or SrtA XS236 is obtained, wherein the amino acid sequence of SrtA XS228 is shown as SEQ ID NO.2, and the amino acid sequence of SrtA XS236 is shown as SEQ ID NO.3.

[0012] Furthermore, in step a, the modular structure of SrtA was predicted using SMART software ( http: / / smart.embl-heidelberg.de / ), InterProScan ( http: / / www.ebi.ac.uk / interpro / scan.html ) and NCBI ( https: / / blast.ncbi.nlm.nih.gov / Blast.cgi ).

[0013] In step b, the specific sites for modifying the SrtA sequence are: 2 (K→A), 7 (R deletion), 21 (Y→L), 41 (I→T), 43 (Q→X), 59 (Q→X), 60 (Q→R), 64 (Q→X), 78 (I→D), 87 (V→P or deletion), 96 (Q→X), 113 (Q→X), 117 (I→T), 120 (H→F), 129 (Q→X), 139 (G→A), 160 (D→P), 172 (Q→X), 178 (Q→X), 185 (D→C). A total of 509 sequences were obtained by performing different permutation groups based on the above sites.

[0014] In step c, SIFT (Sorting Intolerant From Tolerant) was used to predict the effect of amino acid mutations on protein function, and PolyPhen (Polymorphism Phenotyping) was used to predict the possible effect of mutations on protein structure and function. After preliminary functional screening, FoldX was used to predict structure and stability, and high-scoring sequences were selected again, resulting in 16 sequences being selected.

[0015] In step d, the 16 selected sequences were subjected to enzyme activity experiments, and the sequences with better effects, namely SrtA XS228 and SrtA XS236, were selected.

[0016] The second aspect of the present invention provides a method for preparing a transpeptidase mutant, comprising the following steps: S1. inserting a nucleotide sequence encoding a transpeptidase mutant into an expression vector, and then transforming the vector into an expression engineering bacterium to obtain an expression strain; S2, inoculating the expression strain obtained in step S1 into the culture medium to induce expression; S3, centrifugation to collect bacteria; S4. The bacterial cells in step S3 are broken and purified to obtain the transpeptidase mutant.

[0017] Furthermore, in step S1, the expression vector is pET21, and the engineering bacteria is Escherichia coli BL21 (DE3).

[0018] Further, in step S2, the specific operation steps of inducing expression are: inoculating the expression strain into LB culture medium containing 100 mg / L ampicillin and culturing at 37°C, and when the absorbance OD 600 When the pH reached 0.6, 0.25 mM isopropyl β-D-thiogalactoside (IPTG) was added to induce protein production, and the expression temperature was lowered to 30°C and cultured for another 8 hours.

[0019] Furthermore, in step S3, the specific operation steps of the centrifugation are: harvesting the cells by centrifugation at 12000xg~18000xg for 15~25 minutes, and then resuspending the cell pellet in a buffer; the buffer is 20mM Tris-Cl, the buffer contains 0.1% Triton, and the pH of the buffer is 8.0.

[0020] Furthermore, in step S4, the specific operation steps of the disruption are: the cells are disrupted by passing through a high-pressure homogenizer at 1000 bar (about 15000 psi) for 5 times to obtain a lysate.

[0021] Furthermore, in step S4, the purification operation steps are: collecting the supernatant after centrifuging the lysate, passing the supernatant through an affinity chromatography column, and eluting to obtain the purified transpeptidase mutant.

[0022] Specifically, the affinity chromatography column is a Ni-NTA (Qiagen) column; the protein is eluted on the FPLC system using a linear gradient from 0 mM imidazole buffer A (500 mM NaCl, 20 mM Tris-Cl, pH 7.5) to 400 mM imidazole buffer B (400 mM Imidazol, 20 mM Tris-Cl pH 7.5); the target protein is reduced with 1 mM DTT for 1 hour and dialyzed against 50 mM Tris-Cl, 150 mM NaCl and 5 mM CaCl2, pH 7.5 (molecular weight cutoff 3500 Da) to obtain the purified transpeptidase mutant.

[0023] Furthermore, the purified transpeptidase mutants were stored at -20°C until use.

[0024] In a third aspect of the present invention, a transferase mutant is provided, wherein the transferase mutant can recognize a polypeptide or protein containing a (L / F / A / D / S / G)+(P / A)+XTG sequence at the C-terminus and a glycine residue at the N-terminus, wherein X represents any amino acid residue.

[0025] Furthermore, the SrtA XS228 can recognize a polypeptide or protein having a (L / F / A / D / S / G)+PXTG sequence at the C-terminus.

[0026] Furthermore, the SrtA XS236 can recognize a polypeptide or protein having a (L / F / A / D / S / G)+(P / A)+XTG sequence at the C-terminus.

[0027] Furthermore, the transpeptidase mutant is used in the cyclization of polypeptides or proteins, the connection between polypeptides or proteins, the connection between proteins, and the connection between proteins or polypeptides and other compounds.

[0028] Furthermore, the reaction conditions for using the transpeptidase mutant are: temperature 20-30°C, pH 6.5-8.0, preferably: temperature 23°C, pH 7.5.

[0029] Furthermore, the reaction system using the transpeptidase mutant is: 0.1-0.2M NaCl, 3-10mM CaCl2, 30-80mM Tris-Cl, preferably a buffer containing 0.15M NaCl, 5mM CaCl2, 50mM Tris-Cl.

[0030] As described above, the transpeptidase mutant of the present invention and its preparation method and application have the following beneficial effects: 1. The present invention discloses for the first time a transpeptidase mutant having an amino acid sequence as shown in SEQ ID NO.2 or SEQ ID NO.3, and discloses a nucleotide sequence encoding the transpeptidase mutant; the transpeptidase mutant can recognize a polypeptide or protein having a C-terminal sequence of (L / F / A / D / S / G)+(P / A)+XTG, and has a wider range of applications.

[0031] 2. Under the same conditions, the connection efficiency of the transpeptidase mutant is significantly higher than that of the conventional transpeptidase. The concentration of the polypeptide product successfully connected by the transpeptidase mutant is higher and the transpeptidation effect is better. It can be applied to the cyclization of polypeptides or proteins, the connection between polypeptides or proteins, the connection between proteins, and the connection between proteins or polypeptides and other compounds. BRIEF DESCRIPTION OF THE DRAWINGS

[0032] Figure 1 The ligation efficiency of different transpeptidases for different sequences. DETAILED DESCRIPTION

[0033] The following is a description of the implementation of the present invention by means of specific embodiments. Those skilled in the art can easily understand other advantages and effects of the present invention from the contents disclosed in this specification.

[0034] Example 1 The synthesis of SrtA XS228 includes the following specific steps: S1. Insert the nucleotide sequence shown in SEQ ID NO.5 into the pET21 expression vector, and then transform it into Escherichia coli BL21 (DE3) to obtain an expression strain; S2. The expression strain was cultured in LB medium containing 100 mg / L ampicillin at 37°C. 600 When it reached 0.6, 0.25 mM isopropyl β-D-thiogalactoside (IPTG) was added to induce protein production, and the expression temperature was lowered to 30 °C and culture was continued for 8 h; S3, harvest the cells by centrifugation at 16000xg for 20 min, and resuspend the cell pellet in 20 mM Tris-Cl, 0.1% Triton, pH 8.0; S4, the bacteria were broken by passing through a high pressure homogenizer at 1000 bar (about 15000 psi) for 5 times to obtain a lysate, the lysate was centrifuged at 60000×g for 15 minutes, and then the supernatant was applied to a Ni-NTA (Qiagen) column; The column was washed with 20 mM Tris-Cl, 500 mM NaCl pH 7.5, and the protein was eluted on the FPLC system using a linear gradient from 0 mM imidazole in buffer A (500 mM NaCl, 20 mM Tris-Cl, pH 7.5) to 400 mM imidazole in buffer B (400 mM Imidazol, 20 mM Tris-Cl pH 7.5). The target protein was reduced with 1 mM DTT for 1 hour; The buffer was exchanged by dialysis (molecular weight cutoff 3500 Da) against 50 mM Tris-Cl, 150 mM NaCl, and 5 mM CaCl2, pH 7.5; The purified transpeptidase mutants were stored at -20°C until use.

[0035] Example 2 The synthesis of SrtA XS236 includes the following specific steps: S1. Insert the nucleotide sequence shown in SEQ ID NO.6 into the pET21 expression vector, and then transform it into Escherichia coli BL21 (DE3) to obtain an expression strain; S2. The expression strain was cultured in LB medium containing 100 mg / L ampicillin at 37°C. 600When it reached 0.6, 0.25 mM isopropyl β-D-thiogalactoside (IPTG) was added to induce protein production, and the expression temperature was lowered to 30 °C and culture was continued for 8 h; S3, harvest the cells by centrifugation at 16000xg for 20 min, and resuspend the cell pellet in 20 mM Tris-Cl, 0.1% Triton, pH 8.0; S4, the bacteria were broken by passing through a high pressure homogenizer at 1000 bar (about 15000 psi) for 5 times to obtain a lysate, the lysate was centrifuged at 60000×g for 15 minutes, and then the supernatant was applied to a Ni-NTA (Qiagen) column; The column was washed with 20 mM Tris-Cl, 500 mM NaCl pH 7.5, and the protein was eluted on the FPLC system using a linear gradient from 0 mM imidazole in buffer A (500 mM NaCl, 20 mM Tris-Cl, pH 7.5) to 400 mM imidazole in buffer B (400 mM Imidazol, 20 mM Tris-Cl pH 7.5). The target protein was reduced with 1 mM DTT for 1 hour; The buffer was exchanged by dialysis (molecular weight cutoff 3500 Da) against 50 mM Tris-Cl, 150 mM NaCl, and 5 mM CaCl2, pH 7.5; The purified transpeptidase mutants were stored at -20°C until use.

[0036] Example 3 Performance Verification: 1. The reaction system of the transpeptidase is: 0.15M NaCl, 5mM CaCl2, 50mM Tris-Cl (pH 7.5). 50μM of the chemically synthesized GGGHHHHHH peptide (a short peptide with a His tag) and the test polypeptide shown in Table 1 are connected in a total volume of 20μl at 23°C for 2 hours; Table 1. Test peptide sequences

[0037] 2. Pass the reacted sample through a column of affinity resin containing nickel ions (His tag will bind to nickel ions), wash the column with a buffer containing an appropriate amount of salt to remove the unsuccessfully connected test polypeptide fragments; then use a buffer containing a high concentration of histidine to elute the specifically bound protein, dissociate the His tag protein from the resin, and collect this part of the liquid containing the successfully connected polypeptide; 3. Use 40 kDa and 20 kDa ultrafiltration tubes to concentrate and purify the collected proteins in turn to remove the unconnected His-tagged short peptides. Finally, the final concentration of the protein is determined. The results are shown in Table 2. The effect of the connection is determined based on the final concentration of the protein. Figure 1 shown.

[0038] Table 2. Concentration of the final product after the test peptides were connected by different transpeptidases

[0039] Referring to the results of test peptide No. 1, both conventional transfer peptidase (SrtA) and transfer peptidase mutant (SrtA XS228 or SrtA XS236) can recognize peptides containing the LPXTG sequence at the C-terminus; and, under the same conditions, the concentration of the peptide product successfully connected by the transfer peptidase mutant (SrtA XS228 or SrtA XS236) is higher. It can be seen that the connection efficiency of the transfer peptidase mutant (SrtAXS228 or SrtA XS236) is significantly higher than that of conventional transfer peptidase, and the transfer effect is better.

[0040] Referring to the results for test polypeptide numbers 1 to 6, the transpeptidase mutant SrtA XS228 can recognize polypeptides or proteins containing the (L / F / A / D / S / G)+PXTG sequence at the C-terminus.

[0041] Referring to the results of the test peptides No. 1 to 12, the transpeptidase mutant SrtA XS236 can simultaneously recognize peptides or proteins containing the (L / F / A / D / S / G)+PXTG sequence or the (L / F / A / D / S / G)+AXTG sequence at the C-terminus. The transpeptidase mutant SrtA XS236 has a wider range of applications.

[0042] In summary, the present invention discloses for the first time a transpeptidase mutant (SrtA XS228 or SrtA XS236) of an amino acid sequence as shown in SEQ ID NO.2 or SEQ ID NO.3, and discloses a nucleotide sequence encoding the transpeptidase mutant; the transpeptidase mutant can recognize a polypeptide or protein containing a (L / F / A / D / S / G)+(P / A)+XTG sequence at the C-terminus, and has a wider range of applications; under the same conditions, the concentration of the polypeptide product successfully connected by the transpeptidase mutant is higher, the connection efficiency of the transpeptidase mutant is significantly higher than that of the conventional transpeptidase, and the transpeptidation effect is better. Therefore, the present invention effectively overcomes various shortcomings in the prior art and has a high industrial utilization value.

[0043] The above embodiments are merely illustrative of the principles and effects of the present invention, and are not intended to limit the present invention. Anyone familiar with the art may modify or alter the above embodiments without departing from the spirit and scope of the present invention. Therefore, all equivalent modifications or alterations made by a person of ordinary skill in the art without departing from the spirit and technical concept disclosed by the present invention shall still be covered by the claims of the present invention.

Claims

1. A transpeptidase mutant, characterized in that The invention comprises SrtA XS228 or SrtA XS236, wherein the amino acid sequence of SrtA XS228 is shown in SEQ ID NO.2, the amino acid sequence of SrtA XS236 is shown in SEQ ID NO.3, and the transpeptidase mutant can recognize a polypeptide or protein containing a (L / F / A / D / S / G)+(P / A)+XTG sequence at the C-terminus and a glycine residue at the N-terminus, wherein X represents any amino acid residue.

2. The transpeptidase mutant according to claim 1, characterized in that The DNA molecule encoding the SrtA XS228 has a nucleotide sequence as shown in SEQ ID NO.5; the DNA molecule encoding the SrtA XS236 has a nucleotide sequence as shown in SEQ ID NO.

6.

3. The method for preparing a transpeptidase mutant according to claim 1 or 2, characterized in that: The following steps are involved: S1. inserting a nucleotide sequence encoding a transpeptidase mutant into an expression vector, and then transforming the vector into an expression engineering bacterium to obtain an expression strain; S2, inoculating the expression strain obtained in step S1 into the culture medium to induce expression; S3, centrifugation to collect bacteria; S4. The bacterial cells in step S3 are broken and purified to obtain the transpeptidase mutant.

4. The method for preparing a transpeptidase mutant according to claim 3, characterized in that: In step S1, the expression vector is pET21, and the engineering bacteria is Escherichia coli BL21 (DE3).

5. The method for preparing a transpeptidase mutant according to claim 3, characterized in that: In step S2, the specific operation steps of inducing expression are: inoculating the expression strain into LB culture medium containing 100 mg / L ampicillin and culturing at 37°C. 600 When the pH reached 0.6, 0.25 mM IPTG was added to induce protein production, and the expression temperature was lowered to 30 °C and cultured for another 8 h.

6. The method for preparing a transpeptidase mutant according to claim 3, characterized in that: In step S4, the purification operation steps are: collecting the supernatant after centrifugal lysis, passing the supernatant through an affinity chromatography column, and eluting to obtain the purified transpeptidase mutant.

7. Use of the transpeptidase mutant according to claim 1 or 2.

8. The use of the transpeptidase mutant according to claim 7, characterized in that: The transpeptidase mutant is used in the cyclization of polypeptides or proteins, the connection between polypeptides or proteins, the connection between proteins, and the connection between proteins or polypeptides and other compounds.

9. The use of the transpeptidase mutant according to claim 7, characterized in that: The reaction conditions for applying the transpeptidase mutant are: temperature 20-30° C., pH 6.5-8.

0.

10. The use of the transpeptidase mutant according to claim 7, characterized in that: The reaction system using the transpeptidase mutant is: 0.1-0.2M NaCl, 3-10mM CaCl2, 30-80mM Tris-Cl.